Growth Hormone Deficiency in Adults

Back

Background

The somatotroph cells of the anterior pituitary gland produce growth hormone (GH), which is stimulated by GH-releasing hormone (GHRH) and inhibited by somatostatin, both of which are produced by the hypothalamus.

Adult GH deficiency can be a transition from childhood-onset GH deficiency, or it can be acquired during adulthood. The majority of cases are caused by pituitary tumors or by their treatment with surgery, radiation therapy, or both.[1] Traumatic brain injury is another important cause.[1, 2, 3, 4, 5]

GH deficiency in adults is associated with multiple metabolic changes such as abnormal lipid metabolism (increased total cholesterol and low-density lipoprotein cholesterol [LDL-C], increased triglycerides, and reduced high-density lipoprotein cholesterol [HDL-C]), increased subcutaneous and visceral fat, decreased muscle mass, decreased bone density, and features of the metabolic syndrome.[6, 7, 8] Patients usually present with reduced physical performance, impaired psychological well-being, low exercise performance, and reduced quality of life.[1]

The goals of GH therapy in adults are to improve conditioning, strength, body composition, and quality of life, as well as reduce the burden of potential associated medical conditions such as cardiovascular disease and decreased bone mineral density.

Patients should be educated about the technique of subcutaneous injection of GH.

For patient education resources, see Thyroid and Metabolism Center as well as Growth Hormone Deficiency, Growth Hormone Deficiency Medications, and Growth Hormone Deficiency FAQs.

Etiology

Causes of growth hormone (GH) deficiency can be divided into three categories: acquired, congenital, and idiopathic.[9]

Acquired conditions of GH deficiency include tumors of the pituitary gland or the hypothalamus and metastatic disease; surgery or radiation therapy of the pituitary or hypothalamus; infiltrative diseases such as sarcoidosis, tuberculosis, histiocytosis X, hemochromatosis, and lymphocytic hypophysitis; infarction of the pituitary or hypothalamus (which can be spontaneous, or result from Sheehan syndrome or ischemic stroke); subarachnoid hemorrhage; infections of the central nervous system; and head trauma (during the acute stage of the injury and during the rehabilitation stage).[2, 3, 4, 5, 10, 11] ​[12]

Congenital conditions are caused by genetic abnormalities or structural brain defects. Genetic abnormalities include transcription factor defects (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2), GH-releasing hormone (GHRH) receptor gene defects, GH gene defects, and GH-receptor or post-receptor defects. Structural defects include agenesis of the corpus callosum, septo-optic dysplasia, empty sella syndrome, encephalocele, hydrocephalus, and arachnoid cyst. GH deficiency can occur in association with midline facial defects such as single central incisor, cleft lip, and cleft palate.

In rare cases, no clear etiology can be determined for GH deficiency.[9]

Epidemiology

An estimated 6,000 adults are diagnosed with growth hormone (GH) deficiency every year in the United States.[2] Adult GH deficiency has been estimated to affect 1 in 100,000 people annually, whereas its incidence is approximately 2 cases per 100,000 population when childhood-onset GH deficiency patients are considered.[13, 14] About 15-20% of the cases represent the transition of childhood GH deficiency into adulthood.[13] The incidence rate is higher in males with childhood-onset GH deficiency and in people older than 45 years in the adult GH deficiency group.[13]

The age of presentation of acquired GH deficiency in adults often coincides with the discovery of pituitary tumors, usually between the fourth and fifth decades of life.

History and Physical Examination

History

Patients with growth hormone (GH) deficiency usually have a history of pituitary tumors that may have been treated with surgery or radiation, or they may have had a history of head trauma. Some patients also have manifestations of deficiency of other pituitary hormones, such as gonadal, adrenal, and thyroid hormones.[15] About 15-20% of cases involve transitioning of childhood GH deficiency into adulthood.[13]

The symptoms of GH deficiency in adults are often nonspecific. Reported symptoms include low physical and mental energy, decreased muscle strength and exercise tolerance, increased weight or difficulty losing weight, poor memory, emotional instability, impaired sleep, and decreased quality of life.[15, 16] Some patients are asymptomatic.

Physical examination

Most patients with GH deficiency have a normal physical examination. Some patients may have decreased muscle strength as well as reduced skeletal muscle and lean body mass but increased fat mass, mainly in the abdominal region.[15, 16, 17, 18]

Approach Considerations

Evaluation for growth hormone (GH) deficiency is recommended in patients with hypothalamic-pituitary disease, surgery or radiation therapy in these areas, head trauma, or the presence of other pituitary hormone deficiencies.[15] For patients with childhood-onset GH deficiency, retesting for GH deficiency is indicated after achievement of adult height to determine the need to continue therapy—unless they have known mutations, embryopathic lesions causing multiple hormone deficits, or irreversible structural lesions/damage.[15, 18] In these patients, discontinuing GH therapy for at least 1 month is recommended before retesting. Patients with congenital or irreversible hypothalamic-pituitary structural abnormalities do not require retesting for GH deficiency.[15]

Magnetic resonance imaging (MRI) of the hypothalamic-pituitary region may be used to define the anatomy of this region for the presence of tumors or structural abnormalities.

Dual-energy x-ray absorptiometry (DXA) may be used to assess bone mineral density.

Laboratory Studies

Random serum growth hormone (GH) levels are of little value because of the pulsatile nature of GH secretion.

GH deficiency is suspected by a low level of serum insulin-like growth factor-1 (IGF-1), but a normal IGF-1 level does not exclude the possibility of GH deficiency. The use of stimulation tests is generally required to confirm the diagnosis of GH deficiency.[15] The presence of deficiency of three or more pituitary hormones in the context of organic hypothalamic-pituitary disease strongly suggests GH deficiency; in this setting, stimulation testing is not needed[12, 19] or is optional.[15]

The insulin tolerance test (ITT), the combination of GH-releasing hormone (GHRH) and arginine (GHRH-arginine test), glucagon stimulation test, or macimorelin test can be used as stimulation tests for the diagnosis of GH deficiency.[9, 12, 15, 20]

Note: Patients should have adequate replacement of other deficient pituitary hormones before being tested for GH secretion. All stimulation tests are performed after an overnight fast and involve measuring serum GH levels.

ITT

In the ITT, regular insulin is administered intravenously at a dose of 0.1 unit/kg (time 0) to produce a lowering in plasma glucose level to less than 40 mg/dL (2.2 mmol/L). Glucose levels are monitored by capillary samples every 15 minutes and until symptoms of hypoglycemia develop. A repeated dose of insulin can be administered if hypoglycemia does not develop by 30 to 60 minutes. Serum glucose and serum GH levels are measured at 0, 15, 30, 60, 90, and 120 minutes after administering insulin. GH deficiency is diagnosed if the peak GH level is ≤5.1 mcg/L.[12]

Patients usually develop symptoms of hypoglycemia, including sweating, palpitations, and, rarely, convulsions and loss of consciousness. Therefore, the test should be undertaken by an experienced staff under the direct supervision of a physician.

The ITT should be avoided in patients with cardiovascular disease, cerebrovascular disease, or seizure disorders. Because of these safety concerns and laboriousness, the ITT is less frequently used.

GHRH-arginine test

In the GHRH-arginine test, GHRH is administered intravenously at a dose of 1 mcg/kg body weight (time 0), followed by an intravenous infusion of 0.5 g/kg body weight (maximum 30 g) of arginine over 30 minutes. Serum GH is measured at -30, 0, 30, 60, 90, and 120 minutes.

In patients with GH deficiency of hypothalamic origin (eg radiation therapy), GHRH can stimulate the pituitary and, therefore, the GHRH-arginine test can yield falsely normal results.[21] In such cases, using alternative stimulation tests is recommended.

Because body mass index (BMI) can influence the GH response, the following criteria have been used to establish the diagnosis of GH deficiency when using the GHRH-arginine test[12, 15, 18] :

Glucagon stimulation test

If GHRH is not available, the GHRH-arginine test is expected to give inaccurate results, or performing the ITT is either contraindicated or not practical, the glucagon stimulation test[9, 12, 15, 18, 20] or the macimorelin test[18, 22, 23, 24] can be used to diagnose GH deficiency. Because GHRH is not widely available (the only US commercial formulation was discontinued in 2008) and because of safety concerns over the use of ITT, the glucagon stimulation test is increasingly used.[9, 15]

The glucagon stimulation test has become the most commonly used diagnostic test for the diagnosis of GH deficiency because of its availability, reproducibility, safety, and lack of influence by sex and hypothalamic cause of GH deficiency. The test is carried out by administering intramuscular glucagon at a dose of 1 mg (1.5 mg for patients who weigh >90 kg); serum GH levels are measured just before the injection and every 30 minutes for 4 hours.

The following criteria are recommended by the American Association of Clinical Endocrinologists to establish a diagnosis of GH deficiency using the glucagon stimulation test[18, 25] :

Macimorelin test

In 2017, the US Food and Drug Administration (FDA) approved macimorelin, an oral ghrelin agonist that stimulates GH, for the diagnosis of adults with GH deficiency.[22] Approval was based on comparative test results between macimorelin and ITT in adult patients with GH deficiency and healthy control subjects.

The macimorelin test has an accuracy comparable to that of the ITT.[26] The test is performed by administering macimorelin as an oral solution at a dose of 0.5 mg/kg body weight. Serum GH levels are measured just before and at 30, 45, 60, and 90 minutes after the administration of macimorelin. GH deficiency is diagnosed if the peak GH level is ≤2.8 mcg/L.[18]

Approach Considerations

Measurement of bone mineral density using dual-energy X-ray absorptiometry (DXA) is suggested in adult patients with growth hormone (GH) deficiency before starting GH therapy. If the initial bone mineral density findings, are abnormal, repeat testing at intervals of 2-3 years is recommended.[18]

Malignancy

Published data do not confirm an association between GH therapy and recurrence or regrowth of pituitary tumors or craniopharyngiomas.[27, 28, 29] However, because of the possible association between increased insulin-like growth factor-1 (IGF-1) levels and the risk of malignancy, there has been a theoretical concern that GH therapy could lead to regrowth of malignancies.[30] Therefore, GH therapy is contraindicated in patients with active malignancy (other than basal-cell or squamous-cell skin cancers) or proliferative or severe nonproliferative diabetic retinopathy.[9, 15, 18]

For adults with a previous history of cancer, GH therapy should be individualized and may be considered at least 5 years after cancer remission and in consultation with the oncologist.[18]

A 2018 population-based study of 6,874 adult French patients treated with recombinant GH in childhood for isolated GH deficiency, short stature associated with low birth weight or length, or idiopathic short stature found an increased risk of bone tumors but not an overall cancer risk in these individuals.[31]

Consultations

Consult with an endocrinologist.

Consult with a neurosurgeon for evaluation of pituitary tumors.

Medical Care

Growth hormone (GH) replacement therapy is provided in the form of human recombinant GH, available in subcutaneous injection form. The starting dose of GH depends on the age and clinical condition of the patient. A dose regimen that is based on age along with dose titration has been associated with less adverse effects compared with a weight-based regimen.[32] The following treatment regimen is suggested[15, 18] :

For patients with adherence issues, a less frequent dose regimen such as alternate days or three times per week using the same total weekly dosage can be used.[15]

Serum insulin-like growth factor-1 (IGF-1) levels are the main determinant for adjusting the dose of GH.[33] No studies are available to guide this decision. A commonly used target is the upper half of the normal range appropriate for age and sex, unless significant side effects develop.[15]

Similarly, no studies are available regarding the optimal length of GH replacement therapy. Patients with childhood GH deficiency who attained adult height and had persistent deficiency on retesting should continue to receive GH therapy.[15]

GH therapy can also be continued indefinitely if benefits such as significant improvement in quality of life and objective improvements in biochemistry, body composition, and bone mineral density are observed.[18] If no objective or subjective benefits are seen after 1 year of treatment, discontinuation of GH therapy should be considered.[15, 18] If patients decide to discontinue GH therapy, a 6-month follow-up appointment is recommended, as some patients may choose to resume therapy if they felt unwell while off treatment.

Somapacitan, a once-weekly form of GH, has been approved by the FDA for use in adults with GH deficiency. It has been shown to improve body composition parameters (including reduced truncal and visceral fat) and lean body mass.[34]

Long-acting GH formulations can improve patients’ adherence to therapy compared to daily injections. However, further studies are required to assess their methods of dose adjustment, timing of monitoring of IGF-I, efficacy, cost-effectiveness and long-term safety.[35]

Patients on hormone replacement therapy

Patients who are on testosterone-replacement therapy may require their GH doses to be lowered, because testosterone can potentiate GH action and exacerbate GH-induced adverse effects.[36]

Women who are taking oral estrogen replacement therapy usually need higher doses of GH, but those on transdermal estrogen preparations may not.[37]

Adverse effects

The most common side effects of GH therapy are related to fluid retention and include paresthesia, joint stiffness, peripheral edema, arthralgia, myalgia, carpal tunnel syndrome, and increased blood pressure. Most of these adverse effects improve with dose reduction. Older age, higher body mass index (BMI), and female sex confer higher risk of these complications.[38]

GH therapy is associated with a mild increase in both fasting serum glucose and fasting plasma insulin levels.[39] Patients with diabetes mellitus who receive GH therapy may require adjustment in their glucose-lowering medications.

Monitoring

GH therapy may increase the activity of the cytochrome P-450 system and alter the clearance of some medications known to be metabolized by this system, such as corticosteroids, anticonvulsants, sex steroids, and cyclosporine. Therefore, monitoring is advised when such medications are used in patients receiving GH therapy.

GH therapy can decrease levels of serum free T4 and cortisol, therefore, regular monitoring of thyroid and adrenal function is recommended. Patients on concurrent thyroid or adrenal hormone replacement may need dose adjustments after starting GH therapy. Patients who have normal thyroid and adrenal function require monitoring of serum free T4 and assessment of the hypothalamic-pituitary-adrenal axis, because GH therapy can unmask central hypothyroidism and hypoadrenalism.[40, 41]

Follow-up

Follow-up is usually planned at intervals of 1-2 months when the dose of GH can be adjusted by increments of 0.1-0.2 mg/day based on the clinical response, serum IGF-1 levels, and side effects. Longer time intervals and smaller dose increments are suggested for older patients.

Once maintenance doses of GH are achieved, follow-up is provided at intervals of 6 months. Monitoring includes clinical parameters (blood pressure, pulse, body mass index, and waist circumference), assessment of side effects, and measurement of serum IGF-1, fasting glucose, hemoglobin A1C, and lipid profile. Quality of life (QOL) is also assessed using standardized questionnaires that reflect a variety of health-related, economic, and social factors.[42, 43] This is assessed before starting GH treatment and at 12-month intervals.[18]

Complications

Growth hormone (GH) deficiency has been associated with cardiovascular disease, osteopenia/osteoporosis, alteration in body composition, decreased life expectancy, psychological disturbances, insulin resistance, impaired glucose metabolism, and decreased quality of life.​

Cardiovascular disease

Early epidemiologic data showed that patients with hypopituitarism who were on hormone replacement therapy, not including GH, had increased cardiac and cerebrovascular events, suggesting an association of GH deficiency with cardiovascular disease.[12, 44, 45, 46, 47, 48] Patients with GH deficiency have increased rates of the presence of markers of cardiovascular disease, such as greater intima-media thickness of the carotid arteries, reduced left ventricular mass and left ventricular function, decreased ejection fraction, high levels of serum low-density lipoprotein cholesterol (LDL-C) and triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C), elevated inflammatory markers (eg, C-reactive protein, proinflammatory cytokines, adipokines), and high coronary calcium scores.[12, 45, 48, 49, 50, 51, 52, 53]

GH therapy improves certain markers of cardiovascular disease, such as serum lipids (reduction of LDL-C levels and increase in HDL-C levels), systolic function, intima-media thickness of the carotid arteries, endothelial function, inflammatory markers, left ventricular mass, and cardiac output.[46, 48, 50, 53, 54, 55, 56, 57, 58, 59] However, evidence is limited regarding the effect of GH replacement therapy on cardiovascular morbidity and mortality.[46, 47, 48, 60]

A study that evaluated the prevalence of metabolic syndrome and associated cardiovascular complications in adult-onset GH deficiency during GH replacement therapy found an essentially unchanged prevalence of metabolic syndrome in these patients during 1 year of GH therapy. There was a reduction in abnormal waist circumference as well as a decrease in HDL-C levels and worsening in glucose metabolism.[61]

Osteopenia/osteoporosis

Patients with GH deficiency have reduced bone mineral density and increased rates of fractures.[62, 63, 64, 65, 66] About 20% of adult-onset and 35% of childhood-onset adult patients with GH deficiency have osteoporosis.[15] GH therapy improves bone mineral density, but there are no adequately powered controlled studies on its effect on fracture rate.[62, 67, 68]

A gender difference in the response to GH treatment has been hypothesized, as bone mineral density has been shown to improve with this therapy more in men than in women.[69, 70] The effect of GH therapy on fracture rate was less pronounced, with stabilization of the incidence of clinical fracture after GH treatment.[51]

Effect on body composition and physical performance

Patients with GH deficiency tend to have a relative increase in fat mass with a preferential increase in visceral fat and a relative decrease in muscle mass.[71, 72] GH therapy decreases total body fat and increases muscle mass.[72, 73] Some, but not all, studies have shown increased muscle strength along with improved exercise capacity and physical performance after GH therapy.[74, 75, 76, 77, 78, 79]

In an observational, single-center study of 47 patients with GH deficiency who were treated with GH during childhood, investigators evaluated changes in pediatric growth parameters relative to an increase of insulin-like growth factor-1 (IGF-I) z-score as well as other indexes of GH response, such as body composition and lipid profile, after 1 year of treatment in adulthood.[80] The investigators noted the following[80] :

Insulin resistance

Impaired glucose metabolism characterized by insulin resistance, fasting hyperinsulinemia, and impaired glucose tolerance has been reported in patients with GH deficiency.[20, 81, 82]

Decreased life expectancy

Patients with hypopituitarism have decreased life expectancy compared with age- and sex-matched healthy people despite replacement with adrenal, thyroid, and gonadal hormones, primarily owing to cardiovascular and cerebrovascular disease.[15, 83, 84, 85, 86, 87, 88, 89] Therefore, it has been speculated that GH deficiency in patients with hypopituitarism is associated with premature mortality.[15] However, other factors potentially contribute to the increased mortality in these patients, including the following[15] :

There are no published studies on the effect of GH therapy on mortality. Observational data suggest a lower mortality in those who receive GH therapy compared to those who remain untreated, but these findings may be a result of selection bias.[60, 89]

Psychological disturbances/quality of life

Relative to matched healthy persons, patients with GH deficiency have lower quality-of-life scores, with reduced energy, social isolation, and disturbed sexual life.[45, 90, 42, 91]

Studies of quality of life of patients with GH deficiency have shown significant variability, ranging from severe impairment of quality of life to normal quality of life.[7] Reported complaints have included reduced energy levels, mental fatigue, social isolation, anxiety, reduced self-confidence, disturbed sex life, decreased physical mobility, dissatisfaction with body image, poor memory, and reduced cognitive function.[92]

Some, but not all, studies showed improvement in quality of life after patients received GH replacement therapy.[45, 90, 42, 91, 92] Improvement in quality of life was similar regardless of the etiology of GH deficiency, and much of the improvement occurred within the first year of treatment.

2019 American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines

Guidelines for the management of growth hormone (GH) deficiency in adults and patients transitioning from pediatric to adult care were published in 2019 by the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE).[18] Select recommendations are summarized below.

In the setting of clinical suspicion of adult GH deficiency, it is crucial to establish the diagnosis before considering replacement therapy with recombinant human GH (rhGH).

Consider the possibility of adult GH deficiency in patients with a history of hypothalamic-pituitary disease.

It is important to recognize the differences in the etiology of childhood-onset GH deficiency (CO-GHD) versus adult-onset GH deficiency (AO-GHD). Because CO-GHD occurs during the developmental years, adults with this condition may have been GH-deficient for a longer period than patients with AO-GHD.

GH–stimulation testing should be performed to confirm the diagnosis, as random serum GH and insulin-like growth factor-1 (IGF-1) levels cannot be used alone to diagnosis adult GH deficiency.

Use the insulin tolerance test (ITT) to establish a diagnosis of GH deficiency. If this test is contraindicated, then use the glucagon stimulation test or macimorelin stimulation test instead.

Perform one GH-stimulation test to confirm the diagnosis in patients with two or fewer pituitary hormone deficiencies (PHD), as low-serum IGF-1 levels alone are not sufficient to make a diagnosis of adult GH deficiency.

Use body mass index (BMI)–appropriate GH cut-points to diagnose adult GH deficiency. Use the GH cut-point of 3 μg/L for normal-weight (BMI < 25 kg/m2) and overweight (BMI 25 to 30 kg/m2) patients with a high pretest probability, and a lower GH cut-point of 1 μg/L for obese (BMI >30 kg/m2) and overweight (BMI 25 to 30 kg/m2) patients with a low pretest probability.

Closely monitor adults with CO-GHD caused by structural pituitary or brain tumors during their transition to adult-care services. These patients tend to have lower bone mineral density, impaired bone microarchitecture, and more adverse body composition abnormalities and cardiovascular risk markers than patients with AO-GHD.

Individualize rhGH replacement therapy and initiate at low dosages. Suggested starting doses are as follows:

Lower starting rhGH doses (eg, 0.1-0.2 mg/day) are recommended for those with concurrent diabetes mellitus or previous gestational diabetes, obesity, and older age.

Reduce rhGH dosing in the elderly, patients with elevated serum IGF-1, persons discontinuing use of oral estrogen or changing from oral to transdermal estrogen, individuals with worsening glucose tolerance, or those who have fluid retention-related side effects.

After starting rhGH therapy, follow patients at 1- to 2-month intervals, increasing the rhGH dose in increments of 0.1 to 0.2 mg/day.

Never use rhGH replacement therapy for age-related conditions or to enhance athletic performance.

2011 Endocrine Society Guidelines

The Endocrine Society clinical practice guideline on the evaluation and treatment of adult growth hormone (GH) deficiency includes the following recommendations[15] :

Somatropin (Genotropin, Humatrope)

Clinical Context:  Human recombinant growth hormone is produced by recombinant deoxyribonucleic acid (DNA) technology. It stimulates the growth of linear bone, skeletal muscle, and organs and stimulates erythropoietin, increasing red blood cell mass. Actions are either direct or from the hepatic production of IGF-I. It is currently widely available in subcutaneous injection form. 

Somapacitan (Sogroya, somapacitan-beco)

Clinical Context:  Long-acting growth hormone indicated for replacement in adults with growth hormone deficiency. Administered by SC injection once-weekly.

Class Summary

Recombinant growth hormone analogs are indicated for replacement therapy in patients with growth hormone deficiency.

Macimorelin (Macrilen)

Clinical Context:  Macimorelin is an oral ghrelin agonist. Ghrelin is a neuropeptide released mainly from cells in the stomach and pancreas in response to hunger and is a growth hormone-releasing peptide. It stimulates GH release by activating GH secretagogue receptors present in the pituitary and hypothalamus. Macimorelin is indicated for diagnosis of adult growth hormone deficiency.

Class Summary

Macimorelin is the first oral test available for diagnosis of GH deficiency.

What is adult growth hormone (GH) deficiency?What causes adult growth hormone (GH) deficiency?What is the prevalence of adult growth hormone (GH) deficiency?Which clinical history findings are characteristic of adult growth hormone (GH) deficiency?Which physical findings are characteristic of adult growth hormone (GH) deficiency?What are the differential diagnoses for Growth Hormone Deficiency in Adults?What is included in the workup of adult growth hormone (GH) deficiency?What is the role of lab tests in the workup of adult growth hormone (GH) deficiency?What are the diagnostic criteria for adult growth hormone (GH) deficiency?How is adult growth hormone (GH) deficiency treated?Which specialist consultations are beneficial to patients with adult growth hormone (GH) deficiency?What are the possible complications of adult growth hormone (GH) deficiency?What is the risk for cardiovascular disease in adult growth hormone (GH) deficiency?What is the risk for osteopenia or osteoporosis in adult growth hormone (GH) deficiency?What is the effect of adult growth hormone (GH) deficiency on body composition?How does adult growth hormone (GH) deficiency affect life expectancy?How does adult growth hormone (GH) deficiency affect quality-of-life?How does adult growth hormone (GH) deficiency affect glucose metabolism?What are the Endocrine Society guidelines on adult growth hormone (GH) deficiency?What is the goal of drug treatment for adult growth hormone (GH) deficiency?Which medications in the drug class Diagnostic Agents are used in the treatment of Growth Hormone Deficiency in Adults?Which medications in the drug class Growth Hormone Analogs are used in the treatment of Growth Hormone Deficiency in Adults?Which medications in the drug class are used in the treatment of Growth Hormone Deficiency in Adults?

Author

Mohsen S Eledrisi, MD, FACP, FACE, Senior Consultant, Department of Medicine/Endocrinology, Hamad Medical Corporation, Qatar

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

George T Griffing, MD, Professor Emeritus of Medicine, St Louis University School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Ali A Al-Qarni, MD, Consulting Endocrinologist, King Abdulaziz National Guard Hospital, Saudi Arabia, contributed to previous versions of this article.

References

  1. Brabant G, Poll EM, Jonsson P, Polydorou D, Kreitschmann-Andermahr I. Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations?. Eur J Endocrinol. 2009 Nov. 161 suppl 1:S25-31. [View Abstract]
  2. Tanriverdi F, Schneider HJ, Aimaretti G, Masel BE, Casanueva FF, Kelestimur F. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev. 2015 Jun. 36(3):305-42. [View Abstract]
  3. Tanriverdi F, Kelestimur F. Neuroendocrine disturbances after brain damage: an important and often undiagnosed disorder. J Clin Med. 2015 Apr 28. 4(5):847-57. [View Abstract]
  4. Guaraldi F, Grottoli S, Arvat E, Ghigo E. Hypothalamic-pituitary autoimmunity and traumatic brain injury. J Clin Med. 2015 May 19. 4(5):1025-35. [View Abstract]
  5. Tanriverdi F, Kelestimur F. Classical and non-classical causes of GH deficiency in adults. Best Pract Res Clin Endocrinol Metab. 2017 Feb. 31(1):3-11. [View Abstract]
  6. Gola M, Bonadonna S, Doga M, Giustina A. Clinical review: growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab. 2005 Mar. 90(3):1864-70. [View Abstract]
  7. Claessen KM, Appelman-Dijkstra NM, Adoptie DM, et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab. 2013 Jan. 98(1):352-61. [View Abstract]
  8. Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012 Jan. 166(1):13-20. [View Abstract]
  9. Melmed S. Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab. 2013 Jun. 98(6):2187-97. [View Abstract]
  10. Giuliano S, Talarico S, Bruno L, Nicoletti FB, Ceccotti C, Belfiore A. Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury. Endocrine. 2017 Oct. 58(1):115-23. [View Abstract]
  11. Kreber LA, Griesbach GS, Ashley MJ. Detection of growth hormone deficiency in adults with chronic traumatic brain injury. J Neurotrauma. 2016 Sep 1. 33(17):1607-13. [View Abstract]
  12. [Guideline] Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. 2009 Sep-Oct. 15 suppl 2:1-29. [View Abstract]
  13. [Guideline] Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016 Feb. 174(2):P1-9. [View Abstract]
  14. Stochholm K, Gravholt CH, Laursen T, et al. Incidence of GH deficiency - a nationwide study. Eur J Endocrinol. 2006 Jul. 155(1):61-71. [View Abstract]
  15. [Guideline] Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jun. 96(6):1587-609. [View Abstract]
  16. Mo D, Blum WF, Rosilio M, Webb SM, Qi R, Strasburger CJ. Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. J Clin Endocrinol Metab. 2014 Dec. 99(12):4581-8. [View Abstract]
  17. Gasco V, Caputo M, Lanfranco F, Ghigo E, Grottoli S. Management of GH treatment in adult GH deficiency. Best Pract Res Clin Endocrinol Metab. 2017 Feb. 31(1):13-24. [View Abstract]
  18. [Guideline] Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019 Nov. 25(11):1191-232. [View Abstract]
  19. Hartman ML, Crowe BJ, Biller BM, et al, for the HyposCCS Advisory Board, US HypoCCS Study Group. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?. J Clin Endocrinol Metab. 2002 Feb. 87(2):477-85. [View Abstract]
  20. Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002 May. 87(5):2067-79. [View Abstract]
  21. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003 Jan. 88(1):95-102. [View Abstract]
  22. US Food and Drug Administration. NDA approval [letter]. NDA 205598. Available at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205598Orig1s000ltr.pdf. December 20, 2017; Accessed: January 8, 2018.
  23. Agrawal V, Garcia JM. The macimorelin-stimulated growth hormone test for adult growth hormone deficiency diagnosis. Expert Rev Mol Diagn. 2014 Jul. 14(6):647-54. [View Abstract]
  24. Garcia JM, Biller BMK, Korbonits M, et al. Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocr Connect. 2021 Jan. 10(1):76-83. [View Abstract]
  25. [Guideline] Yuen KC, Tritos NA, Samson SL, Hoffman AR, Katznelson L. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency. Endocr Pract. 2016 Oct. 22(10):1235-44. [View Abstract]
  26. Macrilen (macimorelin) [package insert]. Goettingen, Germany: Aeterna Zentaris GmbH. Revised January 2018. Available at
  27. Arnold JR, Arnold DF, Marland A, Karavitaki N, Wass JA. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf). 2009 Mar. 70(3):435-8. [View Abstract]
  28. Buchfelder M, Kann PH, Wuster C, et al. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol. 2007 Aug. 157(2):149-56. [View Abstract]
  29. Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf). 2006 May. 64(5):556-60. [View Abstract]
  30. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer?. Clin Endocrinol (Oxf). 2006 Feb. 64(2):115-21. [View Abstract]
  31. Poidvin A, Carel JC, Ecosse E, Levy D, Michon J, Coste J. Increased risk of bone tumors after growth hormone treatment in childhood: A population-based cohort study in France. Cancer Med. 2018 Jun 14. 7(7):3465-73. [View Abstract]
  32. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML, et al. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab. 2004 Jul. 89(7):3224-33. [View Abstract]
  33. Blum WF, Alherbish A, Alsagheir A, et al. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Connect. 2018 Jun. 7(6):R212-R222. [View Abstract]
  34. Johannsson G, Gordon MB, Hojby Rasmussen M, et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020 Apr 1. 105(4):e1358–e1376. [View Abstract]
  35. Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - current status and future considerations. J Clin Endocrinol Metab. 2020 Jun 1. 105(6):e2121-e2133. [View Abstract]
  36. Giannoulis MG, Sonksen PH, Umpleby M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2006 Feb. 91(2):477-84. [View Abstract]
  37. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999 Nov. 84(11):3956-60. [View Abstract]
  38. Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement?. Clin Endocrinol (Oxf). 1995 Aug. 43(2):143-9. [View Abstract]
  39. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004 May. 89(5):2192-9. [View Abstract]
  40. Losa M, Scavini M, Gatti E, et al. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid. 2008 Dec. 18(12):1249-54. [View Abstract]
  41. Giavoli C, Libe R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab. 2004 Nov. 89(11):5397-401. [View Abstract]
  42. Moock J, Albrecht C, Friedrich N, et al. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the study of health in Pomerania. Eur J Endocrinol. 2009 Jan. 160(1):17-24. [View Abstract]
  43. Holmes SJ, McKenna SP, Doward LC, Hunt SM, Shalet SM. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrinol Metab. 1995 Jan 1. 2(1):63-9.
  44. Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 1992 Nov. 37(5):387-97. [View Abstract]
  45. Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab. 2004 Apr. 89(4):1684-93. [View Abstract]
  46. Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004 Jul. 89(7):3306-12. [View Abstract]
  47. Chikani V, Cuneo RC, Hickman I, Ho KK. Growth hormone (GH) enhances anaerobic capacity: impact on physical function and quality of life in adults with GH deficiency. Clin Endocrinol (Oxf). 2016 Oct. 85(4):660-8. [View Abstract]
  48. van Bunderen CC, van Varsseveld NC, Erfurth EM, Ket JC, Drent ML. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf). 2014 Jul. 81(1):1-14. [View Abstract]
  49. De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab. 1992 Sep. 75(3):833-7. [View Abstract]
  50. Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update. J Clin Endocrinol Metab. 2014 Jan. 99(1):18-29. [View Abstract]
  51. Cannavo S, Marini F, Curto L, et al. High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency. J Endocrinol Invest. 2011 Jan. 34(1):32-7. [View Abstract]
  52. Castillo AR, Zantut-Wittmann DE, Neto AM, Jales RM, Garmes HM. Panhypopituitarism without GH replacement: about insulin sensitivity, CRP levels, and metabolic syndrome. Horm Metab Res. 2018 Sep. 50(9):690-5. [View Abstract]
  53. Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol. 2006 Apr. 154(4):537-43. [View Abstract]
  54. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990 Aug 4. 336(8710):285-8. [View Abstract]
  55. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation. 2003 Nov 25. 108(21):2648-52. [View Abstract]
  56. Colao A, Di Somma C, Spiezia S, et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2008 Sep. 93(9):3416-24. [View Abstract]
  57. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol. 2006 Jul. 155(1):79-90. [View Abstract]
  58. Elbornsson M, Gotherstrom G, Boaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013 May. 168(5):745-53. [View Abstract]
  59. Colao A, Di Somma C, Rota F, et al. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab. 2005 Apr. 90(4):2056-62. [View Abstract]
  60. Jorgensen JOL, Juul A. Therapy of endocrine disease: growth hormone replacement therapy in adults: 30 years of personal clinical experience. Eur J Endocrinol. 2018 Jul. 179(1):R47-56. [View Abstract]
  61. Verhelst J, Mattsson AF, Camacho-Hubner C, Luger A, Abs R. The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis. Endocr Connect. 2018 May. 7(5):653-62. [View Abstract]
  62. Appelman-Dijkstra NM, Claessen KM, Hamdy NA, Pereira AM, Biermasz NR. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf). 2014 Nov. 81(5):727-35. [View Abstract]
  63. Wuster C, Abs R, Bengtsson BA, et al, for the KIMS Study Group and the KIMS International Board, Pharmacia Upjohn International Metabolic Database. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001 Feb. 16(2):398-405. [View Abstract]
  64. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 1994 Mar. 78(3):669-74. [View Abstract]
  65. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993 Sep. 129(3):201-6. [View Abstract]
  66. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997 Sep. 137(3):240-5. [View Abstract]
  67. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res. 2002 Jun. 17(6):1081-94. [View Abstract]
  68. Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. 2014 Mar. 99(3):852-60. [View Abstract]
  69. Drake WM, Rodriguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf). 2001 Apr. 54(4):525-32. [View Abstract]
  70. Snyder PJ, Biller BM, Zagar A, et al. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res. 2007 May. 22(5):762-70. [View Abstract]
  71. Beshyah SA, Freemantle C, Thomas E, et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf). 1995 Feb. 42(2):179-89. [View Abstract]
  72. Maiter D, Abs R, Johannsson G, et al. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur J Endocrinol. 2006 Aug. 155(2):253-60. [View Abstract]
  73. Attanasio AF, Bates PC, Ho KK, et al, for the Hypoptiuitary Control and Complications Study International Advisory Board. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database. J Clin Endocrinol Metab. 2002 Apr. 87(4):1600-6. [View Abstract]
  74. Elgzyri T, Castenfors J, Hagg E, Backman C, Thoren M, Bramnert M. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol (Oxf). 2004 Jul. 61(1):113-22. [View Abstract]
  75. Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab. 2008 Nov. 93(11):4413-7. [View Abstract]
  76. Hartman ML, Weltman A, Zagar A, Qualy RL, Hoffman AR, Merriam GR. Growth hormone replacement therapy in adults with growth hormone deficiency improves maximal oxygen consumption independently of dosing regimen or physical activity. J Clin Endocrinol Metab. 2008 Jan. 93(1):125-30. [View Abstract]
  77. Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 2009 Mar. 94(3):809-16. [View Abstract]
  78. Cenci MC, Soares DV, Spina LD, et al. Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary. 2009. 12(4):322-9. [View Abstract]
  79. Gonzalez S, Sathyapalan T, Javed Z, Atkin SL. Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency. Front Endocrinol (Lausanne). 2018. 9:56. [View Abstract]
  80. Thilmany S, Mchirgui L, Brunelle C, Beauloye V, Maiter D, Alexopoulou O. Correlation between the responses to growth hormone (GH) treatment during childhood and adulthood in a monocentric cohort of GH-deficient patients. Horm Metab Res. 2018 Jun. 50(6):462-8. [View Abstract]
  81. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr. 30(2):152-77. [View Abstract]
  82. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017 Sep. 22(3):145-52. [View Abstract]
  83. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf). 1994 Jan. 40(1):111-6. [View Abstract]
  84. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab. 1996 Mar. 81(3):1169-72. [View Abstract]
  85. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010 Jun. 31(3):301-42. [View Abstract]
  86. Lindholm J, Nielsen EH, Bjerre P, et al. Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol (Oxf). 2006 Jul. 65(1):51-8. [View Abstract]
  87. Stochholm K, Gravholt CH, Laursen T, et al. Mortality and GH deficiency: a nationwide study. Eur J Endocrinol. 2007 Jul. 157(1):9-18. [View Abstract]
  88. Nielsen EH, Lindholm J, Laurberg P. Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf). 2007 Nov. 67(5):693-7. [View Abstract]
  89. Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab. 2015 Apr. 100(4):1405-11. [View Abstract]
  90. Koltowska-Haggstrom M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol. 2009 Nov. 161(suppl 1):S51-64. [View Abstract]
  91. Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf). 2002 Sep. 57(3):363-70. [View Abstract]
  92. Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013 Jul. 169(1):R1-14. [View Abstract]
  93. Garcia JM, Biller BMK, Korbonits M, et al. Macimorelin as a diagnostic test for adult growth hormone deficiency. J Clin Endocrinol Metab. 2018 Aug 1. 103(8):3083-93. [View Abstract]
  94. Brod M, Hojbjerre L, Adalsteinsson JE, Rasmussen MH. Assessing the impact of growth hormone deficiency and treatment in adults: development of a new disease-specific measure. J Clin Endocrinol Metab. 2014 Apr. 99(4):1204-12. [View Abstract]
  95. McCallum RW, Petrie JR, Dominiczak AF, Connell JM. Growth hormone deficiency and vascular risk. Clin Endocrinol (Oxf). 2002 Jul. 57(1):11-24. [View Abstract]
  96. Mavromati M, Kuhn E, Agostini H, et al. Classification of patients with GH disorders may vary according to the IGF-I assay. J Clin Endocrinol Metab. 2017 Aug 1. 102(8):2844-52. [View Abstract]
  97. [Guideline] Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 Nov. 101(11):3888-921. [View Abstract]
  98. Ramos-Levi AM, Marazuela M. Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls. Endocrine. 2018 May. 60(2):203-18. [View Abstract]
  99. Johannsson G, Feldt-Rasmussen U, Hakonsson IH, et al, for the REAL 2 Study Group. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018 May. 178(5):491-9. [View Abstract]
  100. Brod M, Beck JF, Hojbjerre L, et al. Assessing the impact of growth hormone deficiency (GHD) in adults: interpreting change of the treatment-related impact measure-adult growth hormone deficiency (TRIM-AGHD). Pharmacoecon Open. 2019 Mar. 3(1):71-80. [View Abstract]